KOD
Kodiak SciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive GLOW2 topline leads to an expedited regulatory path and clear submission timeline; strong uptake expectations in the addressable diabetic retinopathy market and favorable pricing/coverage assumptions drive material upside to the anchor.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.5.
What can break
Commercial uptake and reimbursement uncertainty
Momentum
64
Value
41
Sentiment
71
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $42.00 · Bull $70.00 · Bear $18.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-27 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $35.50
Why
Momentum64 · Δ7d -23.5
Value41 · Δ7d +0.1
Sentiment71 · Δ7d +1.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
64
34% active weight
Current posture
7d trendSoftening
Δ7d
-23.5
Δ21d
-37.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
71
33% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
+16.3
Why this grade
Composite grade B. Momentum 63.9 / Value 41.1 / Sentiment 70.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.31B
Beta
2.65
Shares Out
61M
P/E (TTM) · Derived
-11.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-15.70
Rev YoY
-
EPS YoY
-39.2%
Gross Margin
-
Op Margin
-
Net Debt
-$168.07M
Current Ratio
1.78
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology